Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838713 | 0.81 | ADK (0.43) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL1193460 | 0.71 | HDAC6 (0.48) | ADRA2AADRA2BADRA2CPLAUMEN1 | |
| SCHEMBL27768259 | 0.71 | L3MBTL1 (0.42) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL27619934 | 0.71 | PTK2 (0.47) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL14339841 | 0.71 | PTK2 (0.39) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL4417417 | 0.70 | PTK2 (0.46) | L3MBTL1PTK2SMN1; SMN2MEN1USP2 | |
| SCHEMBL525912 | 0.70 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL28487270 | 0.70 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CL3MBTL1PLAU | |
| SCHEMBL17322362 | 0.69 | NFE2L2 (0.38) | L3MBTL1PTK2SMN1; SMN2MEN1USP2 | |
| SCHEMBL28028214 | 0.69 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CL3MBTL1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ADRA2A 870/4885ADRA2B 1099/4885ADRA2C 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.